Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) EBT (2023 - 2025)

Historic EBT for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's EBT fell 3339.64% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$194.0 million, marking a year-over-year decrease of 5020.98%. This contributed to the annual value of -$160.9 million for FY2024, which is 33700.4% down from last year.
  • Latest data reveals that Zenas BioPharma reported EBT of -$51.5 million as of Q3 2025, which was down 3339.64% from -$52.2 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year EBT high stood at $35.6 million for Q3 2023, and its period low was -$56.5 million during Q4 2024.
  • Moreover, its 3-year median value for EBT was -$38.0 million (2024), whereas its average is -$32.0 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 20837.08% in 2024, then plummeted by 2150.36% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's EBT stood at -$24.8 million in 2023, then plummeted by 128.15% to -$56.5 million in 2024, then rose by 8.91% to -$51.5 million in 2025.
  • Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.8 million during Q1 2025.